Pharmacological Properties of the Hepatoprotector "Gepanorm"
DOI:
https://doi.org/10.51699/ijhsms.v2i3.1296Keywords:
hepato-biliary tract, chronic hepatitis, liver cirrhosis, preparations for the liver, hepatoprotectorAbstract
The article is devoted to the current state of the problem of the pathology of the hepato-biliary tract in the Republic of Uzbekistan today. Wide registration of hepatoprotective drugs for the treatment of patients with chronic hepatitis and liver cirrhosis allows to solve this problem to some extent. However, the high cost of drugs poses a challenge for the government to introduce domestic drugs to ensure the availability of treatment to all segments of the population. Thus, despite significant progress in the strategy for the elimination of chronic hepatitis and cirrhosis of the liver, a number of problems remain relevant and cause significant difficulties in achieving the global goal.
Downloads
References
Indolfi G., Bartolini E., Olivito B., Azzari C., Resti M. Autoimmunity and Extrahepatic Manifestations in Treatment-Naïve Children with Chronic Hepatitis C Virus Infection. Clinical and Developmental Immunology, 2012. doi:10.1155/2012/785627.
Uchaikin V.F., Cherednichenko T.V., Chaplygina G.V., Pisarev A.G. Liv. 52 - a new look at the effectiveness of acute and chronic viral hepatitis in children // Children's infections.2003. №3. URL: https://cyberleninka.ru/article/n/liv-52-novyy-vzglyad-na-effektivnost-pri-ostryh-i-hronicheskih-virusnyh-gepatitah-u-detey (дата обращения: 06.03.2023).
Technical Report. Interim guidance for country validation of viral hepatitis elimination. 2021. № June. 1—96 p.
Trépo C., Chan H.L.Y., Lok A. Hepatitis B virus infection. The Lancet. Lancet Publishing Group, 2014. 384(9959): 2053—2063.
Asatryan M.N., Salman E.R., Kilikovsky V.V., Kiselev K.V., Sipacheva N.B., Semenenko T.A. Study of the processes of distribution of mutant variants of «vaccinal escape» of the hepatitis B virus by means of a computer epidemiological model. Epidemiologiya i infekcionnie bolezni. Aktualnie problem; 2013; 6:34 — 38. (in Russ)
Shi W., Zhang Z., Ling C., Zheng W., Zhu C., Carr M.J., Higgins D.G. Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections. Infect Genet Evol. 2013 Jun; 16:355—61. doi: 10.1016/j.meegid.2013.03.021. Epub 2013 Mar 26. PMID: 23538336
Lucifora J., Protzer U. Attacking hepatitis B virus cccDNA — The holy grail to hepatitis B cure. J. Hepatol. European Association for the Study of the Liver, 2016. 64(1): S41—S48.
Dilmurod K. et al. Structural changes in regional lymph nodes in experimental pulmonary fibrosis //Central Asian Journal of Medical and Natural Science. – 2022. – Т. 3. – №. 3. – С. 488-494.
Э. М., Ш. ., Ш. Ш., М. ., & М. М, Б. . (2022). ФАРМАКОЛОГИЧЕСКИЕ СВОЙСТВА РАСТИТЕЛЬНОГО ЛЕКАРСТВЕННОГО СРЕДСТВА ПЛОДОВ БОЯРЫШНИКА, ЕГО ГИПОТЕНЗИВНОЕ ДЕЙСВИЕ ПРИ КОМПЛЕКСНОЙ ТЕРАПИИ. IJTIMOIY FANLARDA INNOVASIYA ONLAYN ILMIY JURNALI, 114–117. Retrieved from http://sciencebox.uz/index.php/jis/article/view/1374
Midkhatovna S. E. PRECLINICAL ATHEROSCLEROSIS IN YOUNG MEN WITH METABOLIC SYNDROME AND THE POSSIBILITY OF ITS PRIMARY PREVENTION //EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. – 2022. – Т. 2. – №. 2. – С. 30-34.
Midkhatovna S. E. Efficacy and safety of lipid-lowering drugs as primary and secondary prevention of cardiovascular diseases in the elderlyin the uzbekistan //International Journal of Culture and Modernity. – 2022. – Т. 13. – С. 68-75.
Мидатовна, Ш. Э. . (2022). Неорганные Доброкачественные Опухоли: Фиброма. Miasto Przyszłości, 25, 377–379. Retrieved from http://miastoprzyszlosci.com.pl/index.php/mp/article/view/403
Zarifovna, O. O. (2022). Remedy for Correcting Symptoms of Excessive Gas in the Intestines. EUROPEAN JOURNAL OF INNOVATION IN NONFORMAL EDUCATION, 2(12), 73–76. Retrieved from http://inovatus.es/index.php/ejine/article/view/1307
